The DAWN Camostat Trial for Ambulatory COVID-19 Patients
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a prospective, placebo controlled, individually randomized controlled phase III trial
in Primary Care, assessing the efficacy of Camostat in preventing hospital admission or death
in Covid-19 patients.